Combining Glipizide with Trulicity for Type 2 Diabetes Management

Introduction to Combination Therapy

• The American Diabetes Association and European Association for the Study of Diabetes recommend prioritizing organ-protective medications, such as GLP-1 receptor agonists, over sulfonylureas for type 2 diabetes management 4

Clinical Efficacy and Safety

• Dulaglutide is recommended for patients with type 2 diabetes and cardiovascular disease or at very high/high CV risk to reduce cardiovascular events, according to the European Heart Journal 2
• The combination of glipizide and dulaglutide increases hypoglycemia risk, particularly in elderly patients and those with chronic kidney disease, as noted by Praxis Medical Insights 1
• Patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease should prioritize discontinuing glipizide and using dulaglutide with metformin and/or an SGLT2 inhibitor instead, as suggested by the European Heart Journal and Diabetes Care 2, 3

Patient Assessment and Monitoring

• Hypoglycemia risk factors include elderly age, irregular meal patterns, chronic kidney disease, and alcohol use, as identified by Praxis Medical Insights 1
• Cardiovascular disease risk factors include presence of established atherosclerotic CVD, heart failure, or chronic kidney disease, as noted by the European Heart Journal and Diabetes Care 2, 3
• Current glycemic control should be assessed through HbA1c level and frequency of hypoglycemic episodes, according to Diabetologia 4

Treatment Intensification and Long-Term Strategy

• If HbA1c remains above target despite glipizide plus dulaglutide, treatment intensification beyond dual oral/injectable therapy may be necessary, such as adding an SGLT2 inhibitor or transitioning to basal insulin with dulaglutide, as suggested by Diabetologia and Diabetes Care 4, 3
• The combination of glipizide and dulaglutide should be viewed as a transitional strategy, with the goal of tapering off glipizide once dulaglutide achieves glycemic control, thereby eliminating hypoglycemia risk while maintaining cardiovascular and renal protection, as recommended by Diabetologia, European Heart Journal, and Diabetes Care 4, 2, 3